今年以来，人形机器人等人工智能（AI）板块大幅上涨，带动了科技板块的崛起。然而，近日科技股 受到一定冲击，出现较大幅度调整。但随着国家队加大力度以及社会各方积极稳定市场，科技板块再度 崛起。4月25日，中央政治局会议胜利召开，出台多项重磅政策，有效提振市场信心。此后，科技板块 再次崛起，人形机器人等AI板块出现大涨，AI+医疗板块也出现较大幅度回升。 中央政治局会议指出要打造一批新兴支柱产业，推出"战士科创板"，加快实施"人工智能+"行动。这无 疑是推动科技板块再次崛起的重要因素。会议强调利用人工智能技术赋能多领域协同创新，推动未来制 造、未来信息、未来健康等领域技术突破与产业融合，这将对人形机器人等行业产生重大推动作用。 中央政治局会议强调要持续稳定和活跃资本市场，与过去提出的"稳住楼市、股市"相比，增加了"持续 活跃"这一表述，显示出对资本市场支持力度的进一步增强。我国资本市场的稳定性显著增强。 目前，特朗普挑起的关税战引发国内外反对，特朗普面临巨大压力，可能会通过谈判解决贸易争端，这 也为后续行情启动奠定了基础。 今年5月，我将第五次赴美参加2025年巴菲特股东大会。参会前，我计划前往旧金山硅谷与英伟达 ...

Group 1: Domestic Consumption and Investment Opportunities - The report from Tianfeng Securities emphasizes the ongoing focus on domestic consumption trends and identifies three major investment opportunities in a cyclical context [1] - In the dairy sector, continuous policies such as fertility and milk powder subsidies, rising upstream beef prices, and potential turning points in raw milk prices are expected to stimulate the performance of dairy products [1] - For the snack sector, a relatively low base in Q2 2024, coupled with the acceleration of traditional retail channel adjustments and new channel developments, is anticipated to enable snack companies to achieve double-digit growth [1] Group 2: Rare Earth Sector Dynamics - CITIC Securities highlights the recent export control measures on seven types of heavy rare earth elements, which are expected to boost downstream demand and purchasing activity, leading to a slight price increase [2] - China holds approximately 70% of global rare earth mines and 90% of refining and separation capacity, providing a strong countermeasure against U.S. tariff policies [2] - The demand for rare earth materials is projected to surge, particularly in high-performance applications such as humanoid robots, which could significantly exceed the demand from electric vehicles [2] Group 3: AI in Healthcare - Huatai Securities reports that the FDA's recent announcement to reduce or replace animal testing in drug development with AI-based models is set to transform the pharmaceutical landscape [3] - The policy is expected to accelerate the integration of AI in drug discovery and clinical trials, leading to significant advancements in the "AI + healthcare" sector by 2025 [3] - Investment opportunities in innovative drug companies that leverage AI platforms for drug discovery are emphasized as critical [3]